Stoke Therapeutics (STOK) Current Assets (2018 - 2026)

Stoke Therapeutics' Current Assets history runs 9 years deep, the most recent figure standing at $366.7 million for Q1 2026.

• In Q1 2026, Current Assets fell 2.41% year-over-year to $366.7 million; the TTM figure through Mar 2026 stood at $366.7 million (down 2.41% YoY), while the FY2025 annual figure was $305.7 million, up 31.34% from the prior year.
• Current Assets for Q1 2026 stood at $366.7 million, up from $305.7 million in the prior quarter.
• The five-year high for Current Assets was $375.7 million in Q1 2025, with the low at $193.3 million in Q1 2024.
• The 5-year median for Current Assets is $270.0 million (2025), against an average of $272.5 million.
• The sharpest annual moves came in 2024 and 2025: Current Assets retreated 28.48% in 2024, then jumped 94.4% in 2025.
• Stoke Therapeutics' Current Assets stood at $244.1 million in 2022, then fell by 11.77% to $215.3 million in 2023, then increased by 8.09% to $232.8 million in 2024, then surged by 31.34% to $305.7 million in 2025, then grew by 19.95% to $366.7 million in 2026.
• Business Quant data shows STOK's Current Assets at $366.7 million in Q1 2026, $305.7 million in Q4 2025, and $272.4 million in Q3 2025.